Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.5K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

828
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
828
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug management of TB in the intensive care setting: an international multicentre study.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

The WHO mpox public health emergency of international concern declaration: Need for reprioritisation of global public health responses to combat the MPXV Clade I epidemic.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024
Same author

Vaccination for monkeypox prevention in persons with high-risk sexual behaviours to control on-going outbreak of monkeypox virus clade 3.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2022
Same author

The war in Ukraine and potential consequences for the TB epidemic in Europe.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022
Same author

Comparison of patients with severe COVID-19 admitted to an intensive care unit in South Africa during the first and second wave of the COVID-19 pandemic.

African journal of thoracic and critical care medicine·2022
Same author

Xpert® MTB/RIF assay testing on stool for the diagnosis of paediatric pulmonary TB in Tanzania.

Public health action·2021
Same journal

Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realize.

Journal of internal medicine·2026
Same journal

Social jet lag is associated with incident cardiovascular disease independent of sleep duration and cardiac genetic risk.

Journal of internal medicine·2026
Same journal

Multicenter validation of a severity index model for predicting postoperative acute kidney injury.

Journal of internal medicine·2026
Same journal

The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.

Journal of internal medicine·2026
Same journal

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same journal

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K

Inflammation and tuberculosis: host-directed therapies.

A Zumla1, M Rao, S K Parida

  • 1University College London, University College London Hospitals NHS Foundation Trust, London, UK.

Journal of Internal Medicine
|April 11, 2014
PubMed
Summary
This summary is machine-generated.

Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health threat. Host-directed therapies targeting inflammation show promise for improving treatment outcomes and preventing tissue damage in TB patients.

Keywords:
M. tuberculosisdrug-resistant tuberculosishost-directed therapyinflammationmultidrug-resistant tuberculosistuberculosis

More Related Videos

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K

Related Experiment Videos

Last Updated: May 1, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pharmacology

Background:

  • Tuberculosis (TB) is a deadly airborne disease, with multidrug-resistant TB (MDR-TB) presenting a growing challenge due to treatment resistance.
  • MDR-TB strains are increasingly prevalent, complicating treatment and leading to outbreaks driven by airborne transmission of undetected cases.
  • The rise of extensively drug-resistant and treatment-refractory TB necessitates novel therapeutic strategies beyond conventional antimicrobial approaches.

Purpose of the Study:

  • To review current understanding of inflammation in tuberculosis pathogenesis.
  • To explore the potential of host-directed therapies (HDTs) as adjunct treatments for TB.
  • To identify candidate pathways and biological agents for HDTs aimed at improving clinical outcomes and preserving organ function.

Main Methods:

  • Review of current scientific literature on TB inflammation and host-directed therapies.
  • Analysis of emerging therapeutic strategies focusing on modulating host immune responses.
  • Discussion of potential drug targets and biological agents for repurposing in TB treatment.

Main Results:

  • Inflammatory processes in TB can be detrimental, potentially leading to immune exhaustion and tissue damage.
  • Host-directed therapies offer a promising avenue to manage inflammation and enhance anti-TB immune responses.
  • Target-organ-saving strategies, including repurposed drugs, may prevent tissue damage and improve long-term outcomes.

Conclusions:

  • Modulating inflammatory pathways through host-directed therapies is a critical area for TB research.
  • Developing strategies to preserve tissue integrity and achieve sustained immune responses is essential for effective TB management.
  • Further investigation into biological agents and repurposed drugs for HDTs could lead to improved clinical outcomes for TB patients, especially those with drug-resistant forms.